International Cancer Institute

Cancer Care, Research, & Training

Home CLC ICI Lymphoma Preceptorship

CLC ICI Lymphoma Preceptorship

Multidisciplinary management, standards of care, optimal diagnostics, therapies and future perspectives in the care of Lymphoma patients in sub-Saharan Africa.

Eldoret, Kenya


Training Duration:  6 weeks

Course Director: Prof. Fredrick Chite Asirwa MD

Consultant Physician. Medical Oncologist & Hematologist Executive

Director/CEO: International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: Website:


Course Coordination: Dr. Kevin Makori

Head, Office of Education and Training

International Cancer Institute (ICI)

P.O. Box 8088, Code 30100 Eldoret, Kenya

Email: Website:


This educational activity is provided independently by International Cancer Institute (ICI) through the Blueprint Project.

ICI Education & Training Mission Statement


The ICI Preceptorship Program Mission is to measurably contribute to cancer patients’ safety and health outcomes and to support practice improvement by providing CME/CPD activities that enhance the ability of physicians and other healthcare team members to deliver quality and optimal healthcare services.



The purpose of the ICI Preceptorship Program is to develop educational activities that clearly link the needs of the learner/participants with the planning process, format, and delivery of each activity, resulting in high-quality continuing medical education/continued Professional Development opportunities that will increase the knowledge, competence, and performance of health-care providers.


Content Areas


The ICI Preceptorship Program activities include practical, evidence-based, best clinical practice information for a broad variety of common oncology and hematology conditions, innovations in primary and specialty patient care in NCDs, new procedural training, and specialty fora. The appropriate content for each course is determined based on the results of a practice gap analysis relative to the target audience’s scope of practice, as well as the identified expected outcomes. Content is free of commercial bias.


General Target Audience: ICI Preceptorship/CME/CPD activities focus on the needs of generalist and specialist physicians and other multidisciplinary healthcare team members at ICI-affiliated cancer centers nationally and in sub-Saharan Africa as appropriate.


Type of Activities Provided by ICI


In order to accomplish our educational goals, ICI CME uses a range of activity formats based on the content and desired results of the activity. Current offerings include live and video conferenced activities, live regularly scheduled series, internet CME activities, enduring materials, and hands-on skills workshops. ICI also jointly sponsors activities with regional specialty societies, non-profit educational organizations, and government agencies when mutually desired goals and outcomes are best achieved by such relationships.


Expected Results of the Preceptorship Program


ICI Preceptorship/CME/CPD is committed to assessing the impact and effectiveness of its CME/CPD Program. ICI courses are designed to: increase knowledge of new treatments, diagnostic tools, and procedures; improve compliance with the specific evidence-based standard of care protocols; improve competence, performance, and/or patient outcomes; and promote efficient use of resources. We employ assessment methods to evaluate the extent to which our activities result in changes in knowledge, competence, and performance. CME activities in conjunction with quality improvement projects have measurable outcomes to report. An emphasis during the planning process is placed on intended learning and desired change in knowledge, competence, and performance. The ICI Education and Training Office works in collaboration with other departments/offices of the International Cancer Institute and its partners who are involved and interested in quality improvement processes and patient safety.


Target Audience


The primary target audience for this course comprises the multidisciplinary clinical cancer care team members including, but not limited to medical, surgical, and radiation oncologists; fellows; gastroenterologists; nephrologists; neurologists; pathologists; pulmonologists; radiologists; researchers; oncology nurse practitioners and oncology nurses; Oncology pharmacists; Oncology PharmTechs; Oncology clinical officers; physician assistants; and other allied health care professionals.


Statement of Need


New developments in the treatment of Lymphoma are often not widely disseminated, especially in sub-Saharan Africa, resulting in patients not receiving the best or most up-to-date care. Health care providers need current information on all factors related to lymphoma treatment, including screening, diagnosing, surgical and non-surgical strategies, and overall management of patients with colorectal cancer. Successful lymphoma treatment requires complex strategies and it may be difficult for clinicians to select from the various options available for diagnosis and treatment. Opportunities to discuss cases and compare treatment plans with colleagues are necessary for physicians to optimize their care plans through multidisciplinary tumor boards. ICI continues to conduct at least two virtual multidisciplinary tumor boards weekly. This course will augment that educational activity.




At the end of this educational activity, participants should be able to:

  1. To learn about lymphoma outcome data in Kenya and sub-Saharan Africa (SSA)
  2. To highlight the pathological basis of lymphoma classification
  3. To understand the role of multidisciplinary team in lymphoma management
  4. To understand the role of PET in staging, re-staging, and follow-up
  5. To review the treatment strategy for the most common lymphoma types
  6. To understand the management of lymphomas in HIV populations
  7. To understand the role of Palliative and supportive care in lymphoma management
  8. To discuss clinical cases between faculty and participants

Disclosure of Conflicts of Interest


International Cancer Institute (ICI) requires instructors, planners, managers, and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by ICI for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.


The faculty must report any financial relationships or contractual relationships they or their spouse/life partner have with commercial interests related to the content of this continuing education activity.




Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.


Disclosure of Unlabeled Use


This educational activity may contain a discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.


The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.


Method of Participation and Request for Credit


To receive credit for this activity, participants must review the activity information including learning objectives and faculty/planner disclosures, and actively participate in the educational activity. Upon successfully completing the post-test with a score of 75% or better and the post-activity evaluation, your certificate will be made available immediately.


The Program




Orientation to the course 

  1. Lymphoma Data in Kenya and SSA
  2. Pathologic basis of lymphoma Classification 
  3. Approach to the management of a Lymphoma Patient 
  4. Treatment of Lymphoma I
  5. Treatment of Lymphoma II
  6. Role of PET/CT in management of Lymphoma
  7. Role of Radiotherapy in management of Lymphoma 
  8. Management of lymphomas in HIV, HBV/HCV, Pregnant and Geriatric populations
  9. Stem Cell transplant in Lymphoma
  10. Supportive and Palliative care in Lymphoma
  11. Clinical cases in Lymphoma Management


CMP 100: ICI Lymphoma Preceptorship Course Schedule


Participants should be willing to spend at least 4 hours per week on this online course over a period of 6 weeks. (Duration 32 hours). This program will start when the class is fully subscribed. The course cost is $200.00 for the entire course. There are few sponsorships available on a first-come basis for those who apply. Priority will be given to those working in cancer centers that have formal affiliations/Partnerships with the International Cancer Institute. Apply for sponsorship during the registration of the course


All those interested in registering for this course, please register your information on  if you have any questions or queries please send an email to or


For more information visit our website

International Cancer Institute (ICI) ©2022

Your Partner in Cancer Control in SSA


CLC103 ICI Lymphoma Preceptorship


SKU: N/A Category: Tag:


Subscribing to the course

You can purchase the entire course at Ksh. 20,000 ($200) or choose units you are interested in at Ksh. 2,000 ($20) per unit.

  1. Lymphoma Data in Kenya and SSA
  2. Pathologic basis of lymphoma Classification
  3. Approach to the management of a Lymphoma Patient
  4. Treatment of Lymphoma I
  5. Treatment of Lymphoma II
  6. Role of PET/CT in the management of Lymphoma
  7. Role of Radiotherapy in the management of Lymphoma
  8. Management of lymphomas in HIV, HBV/HCV, Pregnant and Geriatric populations
  9. Stem Cell Transplant in Lymphoma
  10. Supportive and Palliative care in Lymphoma
  11. Biosimilars in Lymphoma Management
  12. Research priorities & Clinical Trial Opportunities in Lymphoma in SSA

Additional information


Lymphoma Data in Kenya and SSA, Pathologic basis of lymphoma Classification, Approach to the management of a Lymphoma Patient, Treatment of Lymphoma I, Treatment of Lymphoma II, Role of PET/CT in the management of Lymphoma, Role of Radiotherapy in the management of Lymphoma, Management of lymphomas in HIV, HBV/HCV, Pregnant and Geriatric populations, Stem Cell Transplant in Lymphoma, Supportive and Palliative care in Lymphoma, Biosimilars in Lymphoma Management, Research priorities & Clinical Trial Opportunities in Lymphoma in SSA, Full Course